RYAN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now for an impatient buyer. RYAN is in a clear downtrend (bearish MA stack and negative MACD), and there’s no Intellectia buy signal to override the tape. While fundamentals and hedge-fund activity are constructive and the stock is near support (possible bounce), the current trend and softening P&C cycle narrative make risk/reward unattractive for an immediate entry. Best stance: hold/avoid new buys until price reclaims the pivot (~49.59) or momentum turns.
Trend is bearish: SMA_200 > SMA_20 > SMA_5 confirms a downward structure. MACD histogram is negative (-0.265) and only mildly contracting, implying downside momentum is easing but not reversed. RSI_6 at ~31.9 is near oversold, supporting a potential short-term bounce, but not a confirmed reversal. Key levels: immediate support S1 ~46.89 (then S2 ~45.21); resistance/pivot ~49.59, then R1 ~52.30. Pattern-based projection is modest (next day ~-0.31%, next week ~+0.23%, next month ~+1.97%), suggesting limited upside unless trend improves.
Intellectia Proprietary Trading Signals:
with revenue +24.79% YoY, net income +73.10% YoY, EPS +122.22% YoY. Hedge funds are buying aggressively (reported buying amount up 53579.79% over the last quarter). Near-term technical setup is close to support with RSI near oversold, which can fuel a reflex bounce. Upcoming catalyst: QDEC 2025 earnings on 2026-02-12 after hours (Street EPS est. 0.50).
alongside elevated IV percentile, suggesting heightened uncertainty/hedging. No supportive news flow in the last week to act as an immediate upside catalyst.
Latest quarter: 2025/Q3. Revenue rose to $754.6M (+24.79% YoY), net income increased to $31.1M (+73.10% YoY), and EPS grew to $0.20 (+122.22% YoY). This indicates strong top-line momentum with improving profitability versus the prior year, supportive for the medium-term thesis even though the near-term technical trend is weak.
Recent Street action shows broadly stable ratings but notable price-target trims into 2026 outlooks: Barclays cut PT to $58 (Overweight), Goldman cut to $61 (Buy), JPM cut to $56 (Underweight), Morgan Stanley cut to $61 (Overweight), while BofA raised to $82 (Buy). Net effect: targets have generally been lowered due to expectations of P&C pricing softening and organic growth headwinds, even as several firms still like the name/selectivity. Wall Street pros: strong company execution, resilience, and growth profile; cons: cycle softening, decelerating pricing/organic growth, and valuation/multiple sensitivity in a tougher broker environment. Politician/congress activity: no recent congress trading data available; no notable politician/influential buying/selling provided. Insider trend is neutral.
